Clinical Trials

Sponsor: Bristol Myers Squibb

Sponsor Study ID: CA224-098

Study Title: A Phase 3, Randomized, Double blind Study of Adjuvant Immunotherapy with Relatlimab and Nivolumab Fixed dose Combination versus Nivolumab Monotherapy after Complete Resection of Stage III IV Melanoma (RELATIVITY 098)

NCT Number: NCT05002569

Phase: III

Protocol Type: Treatment

Age Group: Adults

Disease Sites: Melanoma, Skin

Study Objectives: The purpose of this study is to assess relatlimab and nivolumab fixed-dose combination (FDC) versus nivolumab alone in participants with completely resected stage III-IV melanoma.

For more information about the trial above please contact the study team:

Principal Investigator, Daniel Reuben, at reubend@musc.edu.
Study Coordinator, Jennifer Kinsey, at kinsejen@musc.edu.

Study Documents
(MUSC NetID required for document access)